Retatrutide represents an emerging multi-receptor approach in metabolic treatment, with promising early clinical evidence of its efficacy in weight management and glycemic control. While initial results are encouraging, more long-term studies are needed to fully establish its therapeutic profile.
Post captionshow
R*trutide's Phase 3 data reveals a unique mechanism for weight loss, distinct from other drugs. Understanding its action is key to unlocking its potential.
Video transcriptshow
Retatrutide's phase three trial results just dropped. After actually reading the data myself, I'm not surprised at all. Because for the last 10 weeks, I've been personally experimenting with RETA and I can tell you right now, this is not just a fat loss drug. This is not Ozempic with better marketing. This is definitely not something you can understand through Instagram clips if you never used it …
Show full video transcript
before. As someone who spent years abusing fat burners and stimulants and steroids, Retatrutide is a completely different animal. So in this video, I'm gonna break down the phase three data and what actually it showed because there's parts of this that people are ignoring and why this drug actually behaves differently than semi-glutide and terzeptide. And then I'm gonna walk you through my personal 10-week protocol. I'm gonna talk to you about the dosing, the timing, how I stacked with the other peptides and how I got back down to roughly 8% body fat without wrecking my body and losing my muscle. Let's get into it. Retrutide is a tripital agonist compound, right? So it targets three things, GLP-1, GIP, glucagon. All these receptors are getting hit at the same time. That is a difference right there than your traditional GLP-1s that just suppress your appetite, stop you from eating, and of course you're going to lose weight.
Show lessClaim Breakdown(2 claims found)
“Retatrutide targets three receptors: GLP-1, GIP, and glucagon.”
Multiple peer-reviewed studies confirm retatrutide targets GLP-1, GIP, and glucagon receptors, with a Phase 2 randomized controlled trial providing strong human evidence of its multi-receptor mechanism.
Supporting studies
- 1
Efficacy and safety of retatrutide, a novel GLP-1, GIP, and glucagon receptor agonist for obesity treatment: a systematic review and meta-analysis of randomized controlled trials
Proceedings (Baylor University. Medical Center) · 2025·PMID 40291085
- 2
Is retatrutide (LY3437943), a GLP-1, GIP, and glucagon receptor agonist a step forward in the treatment of diabetes and obesity?
Expert opinion on investigational drugs · 2023·PMID 37086147
- 3
Retatrutide, a GIP, GLP-1 and glucagon receptor agonist, for people with type 2 diabetes: a randomised, double-blind, placebo and active-controlled, parallel-group, phase 2 trial conducted in the USA
Lancet (London, England) · 2023·PMID 37385280
“Traditional GLP-1s just suppress appetite and stop you from eating, leading to weight loss.”
Current research suggests GLP-1 receptor agonists have more complex metabolic effects beyond simple appetite suppression, involving multiple physiological mechanisms including insulin regulation and metabolic signaling.
Supporting studies
Share this audit
Preview post text
✅ AI fact-checked @darkperformancesystems's peptide claims: Verdict: SUPPORTED Retatrutide represents an emerging multi-receptor approach in metabolic treatment, with promising ea… 2 claims checked vs PubMed. Full breakdown 👇 https://peptiq.io/check/2aa936b9-6182-4fb6-a100-21ccb20e1258 @peptiq.io #PeptideScience #Biohacking
Audit another post
3 free per day, no account needed
Track your peptide protocols
Download the PeptIQ app for dosing, logging, and more
This audit is for educational purposes only. Not medical advice. Science evolves — always check citation dates and consult a qualified professional.
Report an error